Consolidated Statements of Cash Flows $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Cash flows used in operating activities:
Net loss	$ (105,316)	$ (132,493)
Adjustments to reconcile net loss to cash used in operating activities:
Stock-based compensation expense	29,662	27,235
Depreciation and amortization	1,818	1,880
Reduction in carrying amount of right-of-use asset	6,421	6,159
Accretion of premium on marketable securities	(5,396)	(3,784)
Amortization of debt discount—related party	0	405
Loss on early extinguishment of debt	0	621
Other	6	77
Changes in operating assets and liabilities:
Accounts receivable	8,697	(10,327)
Prepaid expenses and other current and long-term assets	(4,328)	2,723
Accounts payable	(119)	273
Accrued expenses and other current liabilities	(1,267)	1,316
Operating lease liability	(5,219)	(4,695)
Deferred revenue	9,884	3,772
Net cash used in operating activities	(65,157)	(106,838)
Cash flows provided by investing activities:
Proceeds from maturities of marketable securities	233,231	289,955
Purchase of marketable securities	(284,321)	(129,898)
Purchases of property and equipment	(180)	(1,708)
Net cash (used in) provided by investing activities	(51,270)	158,349
Cash flows provided by financing activities:
Payment of long-term debt − related party	0	(12,500)
Proceeds from exercises of stock options	778	58
Payments for repurchase of common stock for tax withholding	(194)	(110)
Other	382	368
Net cash provided by financing activities	45,336	45,489
Net change in cash, cash equivalents and restricted cash	(71,091)	97,000
Cash, cash equivalents and restricted cash at beginning of period	130,033	33,033
Cash, cash equivalents and restricted cash at end of period	58,942	130,033
Reconciliation of cash, cash equivalents and restricted cash:
Cash, cash equivalents and restricted cash at end of year	58,942	130,033
Less: restricted cash	(3,443)	(3,443)
Cash and cash equivalents at end of the year	55,499	126,590
Supplemental disclosure of cash flow information:
Deferred revenue in accounts receivable	0	10,000
Cash paid for interest - related party	0	990
Cash paid for income taxes	0	1,003
Supplemental disclosures of non-cash investing and financing activities:
Capital expenditures in accounts payable and accrued expenses	0	18
At-The-Market Equity Program
Cash flows provided by financing activities:
Proceeds from issuance of common stock	24,370	57,673
Betta Pharma Stock Purchase Agreement
Cash flows provided by financing activities:
Proceeds from issuance of common stock	$ 20,000	$ 0